February 11, 2019, 09:00 pm

Drug regulator extends review period for use of Incyte drug in treatment of rare disease


 11-02-2019 9:00 PM

Incyte Corp. announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application use of Jakafi for the treatment of patients with acute graft-versus-host disease. Jakafi is Delaware-based Incyte's top drug in total...

Posted in:
Delaware Business Now
Delaware Business Now

This article was posted online by Delaware Business Now. NewsChamber collects excepts of news articles from this news source and add these in the 'Delaware Business'-category.

This story was posted in the category: